Penserra Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Penserra Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,215	Closed	-$32K	–	1542
2021 Q3	$32K	Buy	1,215 +10	+0.8%	+$268	﹤0.01%	1171
2021 Q2	$37K	Buy	1,205 +15	+1%	+$460	﹤0.01%	1068
2021 Q1	$31K	Sell	1,190 -20	-2%	-$559	﹤0.01%	902
2020 Q4	$30K	Buy	1,210 +758	+168%	+$16.3K	﹤0.01%	782
2020 Q3	$9K	Buy	+452	New	+$10.3K	﹤0.01%	826
2018 Q3	–	Sell	-244,371	Closed	-$29M	–	745
2018 Q2	$29M	Buy	+244,371	New	+$12.7M	1.83%	13

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Penserra Capital Management's SUPN Position: Q4 2021 in Review

Penserra Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q4 2021, closing a stake of 1,215 shares — an estimated $32K sold.

Penserra Capital Management first reported a position in SUPN in Q2 2018 and held it in 6 quarters. The position peaked at $29M in Q2 2018. 235 funds tracked by Wall St. Rank hold SUPN as of Q4 2021.

Penserra Capital Management reported no remaining Supernus Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Penserra Capital Management sold 1,215 Supernus Pharmaceuticals shares in Q4 2021, an estimated $32K.
Penserra Capital Management first reported a position in Supernus Pharmaceuticals in Q2 2018 and held it in 6 quarters.
Penserra Capital Management's Supernus Pharmaceuticals position peaked at $29M in Q2 2018.
235 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.